Eighteen months after launch, Ryoncil has crossed $115 million in full-year net revenue, a figure Mesoblast says already exceeds its own initial projections. The fourth quarter alone contributed $36 million, sustaining a growth curve that few cell therapy commercial launches have managed to hold this long after approval. That trajectory matters because the FDA cleared remestemcel-L-rknd in December 2024, meaning Mesoblast generated $115 million from a product that had less than a full calendar year of U.S. commercial history before its fiscal year closed June 30, 2026.
The market position driving that revenue is specific and defensible. Ruxolitinib (Jakafi) holds approval for SR-aGVHD in patients 12 years and older. Ryoncil is approved for children as young as 2 months, a population with no comparable approved MSC option and one where pediatric transplant centers have limited alternatives. Mesoblast is seeing momentum across major U.S. pediatric centers, which aligns with that age-floor advantage. The concentrated nature of that customer base, roughly 150 to 200 high-volume pediatric transplant programs nationally, means penetration depth at a handful of top institutions can move the revenue line materially each quarter.
The more strategically interesting signal in this release is what Mesoblast says it is doing with the cash. A new five-year credit facility has, in the company’s framing, freed the balance sheet to pursue label extension and what it calls blockbuster pipeline assets. Remestemcel-L is in development for adult SR-aGVHD and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being advanced for heart failure and chronic low back pain. None of those programs are cheap, and cell therapy manufacturing at industrial scale is capital-intensive in ways that dilute returns quickly when funded through equity alone. Generating $115 million in product revenue before those programs reach pivotal readouts changes the financing calculus substantially.
The single number worth tracking from here is adult SR-aGVHD trial enrollment pace. If remestemcel-L clears that indication, it enters a larger addressable population and competes directly in the same disease Jakafi already owns in older patients. That head-to-head dynamic, not the pediatric business that is already performing, will define whether Ryoncil becomes a durable franchise or a well-executed niche.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
